Payment overview · 2025
General Payments
$79,624.95
97 reported records · 18 companies
Healthcare provider profile · identity verified
Erik C Spayde, MD
Allopathic & Osteopathic Physicians|Orthopaedic Surgery · THOUSAND OAKS, CA · NPI 1609818822
Verified facts
What the public records show
CMS Open Payments records show Erik C Spayde, MD received $79,624.95 in general payments during 2025 across 97 reported records.
Biogennix, LLC accounted for 74.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 33 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Biogennix, LLC | Unresolved — no canonical attribution shown | $59,627.05 | 74.9% | 2 | 2025 |
| The Institute of Musculoskeletal Science and Education | Unresolved — no canonical attribution shown | $11,906.14 | 14.9% | 2 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $2,564.34 | 3.2% | 23 | 2025 |
| Orthofix Medical, Inc. | Unresolved — no canonical attribution shown | $1,454.95 | 1.8% | 10 | 2025 |
| AxioMed LLC | Unresolved — no canonical attribution shown | $1,418.57 | 1.8% | 4 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $558.40 | 0.7% | 11 | 2025 |
| BIOTRONIK NRO, Inc. | Unresolved — no canonical attribution shown | $545.18 | 0.7% | 13 | 2025 |
| Merit Medical Systems Inc | Unresolved — no canonical attribution shown | $480.86 | 0.6% | 18 | 2025 |
| Arteriocyte Medical Systems, Inc. | Unresolved — no canonical attribution shown | $335.39 | 0.4% | 1 | 2025 |
| Providence Medical Technology, Inc. | Unresolved — no canonical attribution shown | $274.70 | 0.3% | 2 | 2025 |
| Centinel Spine, LLC | Unresolved — no canonical attribution shown | $157.63 | 0.2% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $80.77 | 0.1% | 3 | 2025 |
| GE HEALTHCARE | Unresolved — no canonical attribution shown | $76.83 | 0.1% | 1 | 2025 |
| DJO, LLC | Unresolved — no canonical attribution shown | $51.08 | 0.1% | 2 | 2025 |
| SPR Therapeutics, Inc | Unresolved — no canonical attribution shown | $35.76 | 0.0% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $27.27 | 0.0% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$15.84 | 0.0% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $14.19 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Royalty or License | $71,354.38 | 3 |
| Food and Beverage | $3,549.49 | 85 |
| Travel and Lodging | $2,371.08 | 6 |
| Consulting Fee | $2,350.00 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Orthros Normalized: orthros |
Device | The Institute of Musculoskeletal Science and Education | $11,906.14 | 2 | 2025 |
Source payment records
|
|||||
| Spira Normalized: spira |
Device | The Institute of Musculoskeletal Science and Education | $11,906.14 | 2 | 2025 |
Source payment records
|
|||||
| PULSE Normalized: pulse |
Device | Globus Medical, Inc. | $2,000.00 | 1 | 2025 |
Source payment records
|
|||||
| Freedom Lumbar Disc Normalized: freedom lumbar disc |
Device | AxioMed LLC | $1,418.57 | 4 | 2025 |
Source payment records
|
|||||
| MISCELLANEOUS Normalized: miscellaneous |
Device | Orthofix Medical, Inc. | $1,098.04 | 5 | 2025 |
Source payment records
|
|||||
| Prospera Normalized: prospera |
Device | BIOTRONIK NRO, Inc. | $545.18 | 13 | 2025 |
Source payment records
|
|||||
| Magellan Normalized: magellan |
Device | Arteriocyte Medical Systems, Inc. | $335.39 | 1 | 2025 |
Source payment records
|
|||||
| WaveWriter Alpha Prime 16 Normalized: wavewriter alpha prime 16 |
Device | Boston Scientific Corporation | $287.82 | 5 | 2025 |
Source payment records
|
|||||
| General - Pain Management Normalized: general pain management |
Device | Boston Scientific Corporation | $270.58 | 6 | 2025 |
Source payment records
|
|||||
| STAR Tumor Ablation System Normalized: star tumor ablation system |
Device | Merit Medical Systems Inc | $224.69 | 8 | 2025 |
Source payment records
|
|||||
| NorthStar Normalized: northstar |
Device | Orthofix Medical, Inc. | $185.00 | 1 | 2025 |
Source payment records
|
|||||
| PRODISC C VIVO Normalized: prodisc c vivo |
Device | Centinel Spine, LLC | $157.63 | 1 | 2025 |
Source payment records
|
|||||
| OsteoStrand Normalized: osteostrand |
Device | Orthofix Medical, Inc. | $125.69 | 2 | 2025 |
Source payment records
|
|||||
| XLIF Normalized: xlif |
Device | Globus Medical, Inc. | $96.66 | 4 | 2025 |
Source payment records
|
|||||
| StabiliT System Normalized: stabilit system |
Device | Merit Medical Systems Inc | $87.05 | 10 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $80.77 | 3 | 2025 |
Source payment records
|
|||||
| MODULUS Normalized: modulus |
Device | Globus Medical, Inc. | $74.63 | 3 | 2025 |
Source payment records
|
|||||
| ADIRA Normalized: adira |
Device | Globus Medical, Inc. | $61.23 | 2 | 2025 |
Source payment records
|
|||||
| AIRCAST Normalized: aircast |
Device | DJO, LLC | $51.08 | 2 | 2025 |
Source payment records
|
|||||
| NVM5 Normalized: nvm5 |
Device | Globus Medical, Inc. | $50.14 | 2 | 2025 |
Source payment records
|
|||||
| EXCELSIUS GPS Normalized: excelsius gps |
Device | Globus Medical, Inc. | $49.48 | 3 | 2025 |
Source payment records
|
|||||
| SIMPLIFY CERVICAL ARTIFICIAL DISC Normalized: simplify cervical artificial disc |
Device | Globus Medical, Inc. | $47.27 | 2 | 2025 |
Source payment records
|
|||||
| Lattus Normalized: lattus |
Device | Orthofix Medical, Inc. | $46.22 | 2 | 2025 |
Source payment records
|
|||||
| CORRIDOR Normalized: corridor |
Device | Globus Medical, Inc. | $38.47 | 1 | 2025 |
Source payment records
|
|||||
| SPRINT PNS System Normalized: sprint pns system |
Device | SPR Therapeutics, Inc | $35.76 | 1 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $34.33 | 1 | 2025 |
Source payment records
|
|||||
| Vyrsa V1 Normalized: vyrsa v1 |
Device | Globus Medical, Inc. | $33.58 | 1 | 2025 |
Source payment records
|
|||||
| CREO Normalized: creo |
Device | Globus Medical, Inc. | $28.34 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $27.27 | 1 | 2025 |
Source payment records
|
|||||
| SABLE Normalized: sable |
Device | Globus Medical, Inc. | $25.94 | 1 | 2025 |
Source payment records
|
|||||
| AFFIRM Normalized: affirm |
Device | Globus Medical, Inc. | $24.27 | 1 | 2025 |
Source payment records
|
|||||
| SYNCHROMEDII Normalized: synchromedii |
Device | Medtronic, Inc. | $15.84 | 1 | 2025 |
Source payment records
|
|||||
| PROCLAIM Normalized: proclaim |
Device | Abbott Laboratories | $14.19 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Meloxicam | Meloxicam | 281 | 121 |
| Gabapentin | Gabapentin | 212 | 79 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 131 | 96 |
| Baclofen | Baclofen | 94 | 34 |
| Tramadol Hcl | Tramadol Hcl | 78 | 48 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 74 | 65 |
| Methylprednisolone | Methylprednisolone | 67 | 65 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 66 | 50 |
| Pregabalin | Pregabalin | 45 | 23 |
| Tizanidine Hcl | Tizanidine Hcl | 43 | 30 |
| Celecoxib | Celecoxib | 42 | 13 |
| Oxycodone Hcl | Oxycodone Hcl | 25 | 16 |
| Alprazolam | Alprazolam | 22 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 22 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 21 | 19 |
| Ibuprofen | Ibuprofen | 19 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 13 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 12 | suppressed |
| Amoxicillin | Amoxicillin | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $79,624.95 · 97 records | Biogennix, LLC | ADIRA, AFFIRM, AIRCAST, CORRIDOR, CREO, EVENITY, EXCELSIUS GPS, Freedom Lumbar Disc, General - Pain Management, JOURNAVX, Lattus, MISCELLANEOUS, MODULUS, Magellan, NVM5, NorthStar, Orthros, OsteoStrand, PROCLAIM, PRODISC C VIVO, PULSE, Prospera, SABLE, SIMPLIFY CERVICAL ARTIFICIAL DISC, SPRINT PNS System, STAR Tumor Ablation System, SYNCHROMEDII, Senza, Spira, StabiliT System, Vyrsa V1, WaveWriter Alpha Prime 16, XLIF | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error